Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T25726
(Former ID: TTDI02084)
|
|||||
Target Name |
Glypican-3 (GPC3)
|
|||||
Synonyms |
Secreted glypican3; OCI5; MXR7; Intestinal protein OCI5; Intestinal protein OCI-5; GTR22; GTR2-2
Click to Show/Hide
|
|||||
Gene Name |
GPC3
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 4 Target-related Diseases | + | ||||
1 | Metastatic liver/bile duct neoplasm [ICD-11: 2D80] | |||||
2 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
3 | Lung cancer [ICD-11: 2C25] | |||||
4 | Liver cancer [ICD-11: 2C12] | |||||
Function |
Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins. Binding to the hedgehog protein SHH triggers internalization of the complex by endocytosis and its subsequent lysosomal degradation. Positively regulates the canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands. Positively regulates the non-canonical Wnt signaling pathway. Binds to CD81 which decreases the availability of free CD81 for binding to the transcriptional repressor HHEX, resulting in nuclear translocation of HHEX and transcriptional repression. Inhibits the dipeptidyl peptidase activity of DPP4. Plays a role in limb patterning and skeletal development by controlling the cellular response to BMP4. Modulates the effects of growth factors BMP2, BMP7 and FGF7 on renal branching morphogenesis. Required for coronary vascular development. Plays a role in regulating cell movements during gastrulation. Cell surface proteoglycan that bears heparan sulfate.
Click to Show/Hide
|
|||||
UniProt ID | ||||||
Sequence |
MAGTVRTACLVVAMLLSLDFPGQAQPPPPPPDATCHQVRSFFQRLQPGLKWVPETPVPGS
DLQVCLPKGPTCCSRKMEEKYQLTARLNMEQLLQSASMELKFLIIQNAAVFQEAFEIVVR HAKNYTNAMFKNNYPSLTPQAFEFVGEFFTDVSLYILGSDINVDDMVNELFDSLFPVIYT QLMNPGLPDSALDINECLRGARRDLKVFGNFPKLIMTQVSKSLQVTRIFLQALNLGIEVI NTTDHLKFSKDCGRMLTRMWYCSYCQGLMMVKPCGGYCNVVMQGCMAGVVEIDKYWREYI LSLEELVNGMYRIYDMENVLLGLFSTIHDSIQYVQKNAGKLTTTIGKLCAHSQQRQYRSA YYPEDLFIDKKVLKVAHVEHEETLSSRRRELIQKLKSFISFYSALPGYICSHSPVAENDT LCWNGQELVERYSQKAARNGMKNQFNLHELKMKGPEPVVSQIIDKLKHINQLLRTMSMPK GRVLDKNLDEEGFESGDCGDDEDECIGGSGDGMIKVKNQLRFLAELAYDLDVDDAPGNSQ QATPKDNEISTFHNLGNVHSPLKLLTSMAISVVCFFFLVH Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 19 Clinical Trial Drugs | + | ||||
1 | Codrituzumab | Drug Info | Phase 2 | Hepatic metastasis | [2] | |
2 | GC33 | Drug Info | Phase 2 | Hepatocellular carcinoma | [3] | |
3 | GPC-3298306 | Drug Info | Phase 2 | Hepatocellular carcinoma | [4] | |
4 | RG7686 | Drug Info | Phase 2 | Hepatocellular carcinoma | [3], [5] | |
5 | SAR444200 | Drug Info | Phase 2 | Aggressive cancer | [6] | |
6 | CAR-T cells targeting Glypican-3 (GPC3) | Drug Info | Phase 1/2 | Hepatocellular carcinoma | [7] | |
7 | CAR-T cells targeting GPC3 | Drug Info | Phase 1/2 | Hepatocellular carcinoma | [8] | |
8 | GPC3-CART cells | Drug Info | Phase 1/2 | Hepatocellular carcinoma | [9] | |
9 | Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs | Drug Info | Phase 1/2 | Hepatocellular carcinoma | [10] | |
10 | TAI-GPC3-CART cells | Drug Info | Phase 1/2 | Hepatocellular carcinoma | [11] | |
11 | Anti-GPC3 CAR T | Drug Info | Phase 1 | Hepatocellular carcinoma | [12] | |
12 | CAR-GPC3 T Cells | Drug Info | Phase 1 | Lung squamous cell carcinoma | [13] | |
13 | ERY974 | Drug Info | Phase 1 | Solid tumour/cancer | [14] | |
14 | GAP T cells | Drug Info | Phase 1 | Solid tumour/cancer | [15] | |
15 | GLYCAR T cells | Drug Info | Phase 1 | Hepatocellular carcinoma | [16] | |
16 | GPC3 targeting CAR-T cells | Drug Info | Phase 1 | Hepatocellular carcinoma | [17] | |
17 | TAK-102 | Drug Info | Phase 1 | Solid tumour/cancer | [18] | |
18 | CAR-GPC3 T cell | Drug Info | Clinical trial | Hepatocellular carcinoma | [19] | |
19 | CAR-GPC3 T cells | Drug Info | Clinical trial | Hepatocellular carcinoma | [20] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Inhibitor | [+] 3 Inhibitor drugs | + | ||||
1 | Codrituzumab | Drug Info | [2] | |||
2 | GC33 | Drug Info | [21] | |||
3 | ERY974 | Drug Info | [2] | |||
CAR-T-Cell-Therapy | [+] 12 CAR-T-Cell-Therapy drugs | + | ||||
1 | CAR-T cells targeting Glypican-3 (GPC3) | Drug Info | [7] | |||
2 | CAR-T cells targeting GPC3 | Drug Info | [8] | |||
3 | GPC3-CART cells | Drug Info | [9] | |||
4 | Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs | Drug Info | [10] | |||
5 | TAI-GPC3-CART cells | Drug Info | [11] | |||
6 | Anti-GPC3 CAR T | Drug Info | [12] | |||
7 | CAR-GPC3 T Cells | Drug Info | [13] | |||
8 | GAP T cells | Drug Info | [15] | |||
9 | GLYCAR T cells | Drug Info | [16] | |||
10 | GPC3 targeting CAR-T cells | Drug Info | [17] | |||
11 | CAR-GPC3 T cell | Drug Info | [19] | |||
12 | CAR-GPC3 T cells | Drug Info | [20] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
Degree | 6 | Degree centrality | 6.45E-04 | Betweenness centrality | 1.30E-04 |
---|---|---|---|---|---|
Closeness centrality | 1.93E-01 | Radiality | 1.33E+01 | Clustering coefficient | 6.67E-02 |
Neighborhood connectivity | 1.05E+01 | Topological coefficient | 2.34E-01 | Eccentricity | 13 |
Download | Click to Download the Full PPI Network of This Target | ||||
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 1 KEGG Pathways | + | ||||
1 | Proteoglycans in cancer | |||||
NetPath Pathway | [+] 1 NetPath Pathways | + | ||||
1 | IL2 Signaling Pathway | |||||
PID Pathway | [+] 2 PID Pathways | + | ||||
1 | Glypican pathway | |||||
2 | Glypican 3 network | |||||
Reactome | [+] 3 Reactome Pathways | + | ||||
1 | A tetrasaccharide linker sequence is required for GAG synthesis | |||||
2 | HS-GAG degradation | |||||
3 | Retinoid metabolism and transport | |||||
WikiPathways | [+] 1 WikiPathways | + | ||||
1 | Visual phototransduction |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91. | |||||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 3 | ClinicalTrials.gov (NCT01507168) A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma. U.S. National Institutes of Health. | |||||
REF 4 | Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015 Aug;14(4):361-6. | |||||
REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8406). | |||||
REF 6 | ClinicalTrials.gov (NCT05450562) A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors. U.S.National Institutes of Health. | |||||
REF 7 | ClinicalTrials.gov (NCT02723942) CAR-T Cell Immunotherapy for HCC Targeting GPC3 | |||||
REF 8 | ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy | |||||
REF 9 | ClinicalTrials.gov (NCT03130712) A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) | |||||
REF 10 | ClinicalTrials.gov (NCT03084380) Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) | |||||
REF 11 | ClinicalTrials.gov (NCT02715362) A Study of GPC3 Redirected Autologous T Cells for Advanced HCC | |||||
REF 12 | ClinicalTrials.gov (NCT02395250) Anti-GPC3 CAR T for Treating Patients With Advanced HCC | |||||
REF 13 | ClinicalTrials.gov (NCT02876978) Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma | |||||
REF 14 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 15 | ClinicalTrials.gov (NCT02932956) Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) | |||||
REF 16 | ClinicalTrials.gov (NCT02905188) Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | |||||
REF 17 | ClinicalTrials.gov (NCT03198546) GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression | |||||
REF 18 | ClinicalTrials.gov (NCT04405778) A Study of TAK-102 in Adult With Previously-Treated Solid Tumors. U.S. National Institutes of Health. | |||||
REF 19 | ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | |||||
REF 20 | ClinicalTrials.gov (NCT03146234) CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma | |||||
REF 21 | First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8. | |||||
REF 22 | Clinical pipeline report, company report or official report of Sanofi |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.